Zelgen Pharma to present cancer drug data at ASCO 2025

Zelgen Pharmaceuticals announced that clinical research data on its independently developed drugs, Alveltamig (ZG006) and Nilvanstomig (ZG005), will be presented at the 2025 ASCO Annual Meeting. ZG006 is showing promising results in treating small-cell lung cancer, with an ORR (Objective Response Rate) of 62.5% and 58.3% in the 10mg and 30mg groups, respectively. Additionally, ZG006 is demonstrating efficacy and safety in treating neuroendocrine tumors. ZG005, a PD-1/TIGIT bispecific antibody, has shown a confirmed ORR of 40.9% and DCR of 68.2% in previously treated cervical cancer patients at a dose of 20 mg/kg. Finally, the first-in-class LAG-3/TIGIT bispecific antibody ZGGS15 is also demonstrating promising results. The company cautions that drug development is subject to risk and uncertainty.